Vericel is a biopharmaceutical company based in Ann Arbor, MI, specializing in advanced cell therapy products for the sports medicine and severe burn care markets. They manufacture and market two innovative therapies in the United States, including MACI for cartilage repair and Epicel for burn treatment. Vericel also holds an exclusive license for the North American commercial rights to NexoBrid, a biological orphan product approved for eschar removal in severe thermal burns.
With a focus on addressing unmet needs in these medical fields, Vericel is dedicated to improving patient outcomes and enhancing quality of life. Their advanced therapies have gained recognition and approval from the FDA, offering promising alternatives to traditional treatments. Through ongoing clinical development and research, Vericel continues to expand its pipeline and contribute to the advancement of regenerative medicine.
Generated from the website